603367.SH
辰欣药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 13.61
−3.48%Year over year
Reported trailing growth
- Revenue
- -10.1%
- EBITDA
- —
- EBIT
- -12.0%
- EPS
- -16.7%
- Free cash flow
- +82.1%
- Operating cash flow
- +56.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -5.4%
- EBITDA
- +5.6%
- EBIT
- +11.1%
- Net income
- +6.4%
- EPS
- +6.5%
- Free cash flow
- +21.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026